Jakob Sture Madsen

Jakob Sture Madsen

Auto-generated profile, based on publicly available information

Jakob Sture Madsen

Department of Drug Design and Pharmacology

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 August 2022 in Nature Aging
Verified
Journal Article
Open access
PDF file
IHIndra Heckenbach
Indra Heckenbach
GMGarik V. Mkrtchyan
Garik V. Mkrtchyan
MEMichael Ben Ezra
Michael Ben Ezra
DBDaniela Bakula
Daniela Bakula
JMJakob Sture Madsen
Jakob Sture Madsen
MSMorten Scheibye-Knudsen
Morten Scheibye-Knudsen
Cellular senescence is an important factor in aging and many age-related diseases, but understanding its role in health is challenging due to the lack of exclusive or universal markers. Using neural networks, we predict senescence from the nuclear morphology of human fibroblasts with up to 95% accuracy, and investigate murine astrocytes, murine neurons, and fibroblasts with premature aging in culture. After generalizing our approach, the predictor recognizes higher rates of senescence in p21-positive and ethynyl-2’-deoxyuridine (EdU)-negative nuclei in tissues and shows an increasing rate of senescent cells with age in H&E-stained murine liver tissue and human dermal biopsies. Evaluating medical records reveals that higher rates of senescent cells correspond to decreased rates of malignant neoplasms and increased rates of osteoporosis, osteoarthritis, hypertension and cerebral infarction. In sum, we show that morphological alterations of the nucleus can serve as a deep learning predictor of senescence that is applicable across tissues and species and is associated with health outcomes in humans.

13 June 2024 in Nature Metabolism
Verified
Journal Article
Open access
PDF file
HKHüsün S. Kizilkaya
Hüsün S. Kizilkaya
KSKimmie V. Sørensen
Kimmie V. Sørensen
JMJakob S. Madsen
Jakob S. Madsen
PLPeter Lindquist
Peter Lindquist
JDJon Douros
Jon Douros
MRmette rosenkilde
mette rosenkilde
Incretin-based therapies are highly successful in combatting obesity and type 2 diabetes1. Yet both activation and inhibition of the glucose-dependent insulinotropic polypeptide (GIP) receptor (GIPR) in combination with glucagon-like peptide-1 (GLP-1) receptor (GLP-1R) activation have resulted in similar clinical outcomes, as demonstrated by the GIPR–GLP-1R co-agonist tirzepatide2 and AMG-133 (ref. 3) combining GIPR antagonism with GLP-1R agonism. This underlines the importance of a better understanding of the GIP system. Here we show the necessity of β-arrestin recruitment for GIPR function, by combining in vitro pharmacological characterization of 47 GIPR variants with burden testing of clinical phenotypes and in vivo studies. Burden testing of variants with distinct ligand-binding capacity, Gs activation (cyclic adenosine monophosphate production) and β-arrestin 2 recruitment and internalization shows that unlike variants solely impaired in Gs signalling, variants impaired in both Gs and β-arrestin 2 recruitment contribute to lower adiposity-related traits. Endosomal Gs-mediated signalling of the variants shows a β-arrestin dependency and genetic ablation of β-arrestin 2 impairs cyclic adenosine monophosphate production and decreases GIP efficacy on glucose control in male mice. This study highlights a crucial impact of β-arrestins in regulating GIPR signalling and overall preservation of biological activity that may facilitate new developments in therapeutic targeting of the GIPR system.

19 November 2021 in Journal of Biological Chemistry
Verified
Journal Article
Open access
WVWijnand J.C. van der Velden
Wijnand J.C. van der Velden
PLPeter Lindquist
Peter Lindquist
JMJakob S. Madsen
Jakob S. Madsen
RSRoderick H.M.J. Stassen
Roderick H.M.J. Stassen
NANicolai Wewer Albrechtsen
Nicolai Wewer Albrechtsen
MRmette rosenkilde
mette rosenkilde
Naturally occurring missense variants of G protein–coupled receptors with loss of function have been linked to metabolic disease in case studies and in animal experiments. The glucagon receptor, one such G protein–coupled receptor, is involved in maintaining blood glucose and amino acid homeostasis; however, loss-of-function mutations of this receptor have not been systematically characterized. Here, we observed fewer glucagon receptor missense variants than expected, as well as lower allele diversity and fewer variants with trait associations as compared with other class B1 receptors. We performed molecular pharmacological phenotyping of 38 missense variants located in the receptor extracellular domain, at the glucagon interface, or with previously suggested clinical implications. These variants were characterized in terms of cAMP accumulation to assess glucagon-induced Gαs coupling, and of recruitment of β-arrestin-1/2. Fifteen variants were impaired in at least one of these downstream functions, with six variants affected in both cAMP accumulation and β-arrestin-1/2 recruitment. For the eight variants with decreased Gαs signaling (D63ECDN, P86ECDS, V96ECDE, G125ECDC, R2253.30H, R3085.40W, V3686.59M, and R3787.35C) binding experiments revealed preserved glucagon affinity, although with significantly reduced binding capacity. Finally, using the UK Biobank, we found that variants with wildtype-like Gαs signaling did not associate with metabolic phenotypes, whereas carriers of cAMP accumulation-impairing variants displayed a tendency toward increased risk of obesity and increased body mass and blood pressure. These observations are in line with the essential role of the glucagon system in metabolism and support that Gαs is the main signaling pathway effecting the physiological roles of the glucagon receptor.

9 May 2024 in British Journal of Pharmacology
Verified
Journal Article
Open access
DRDavid Reiner‐Link
David Reiner‐Link
JMJakob Sture Madsen
Jakob Sture Madsen
DGDavid E. Gloriam
David E. Gloriam
HBHans Bräuner-Osborne
Hans Bräuner-Osborne
AHAlexander S. Hauser
Alexander S. Hauser
Background and Purpose: The dopamine D2 receptor is expressed as a short (D2S) and a long (D2L) isoform with 29 additional amino acids in the third intracellular loop. The D2S isoform shows higher presynaptic expression than the D2L isoform, and decreased D2S expression has recently been linked to an increased risk for schizophrenia. Here, we present the first investigation, at receptor isoform level, of kinetic differences in the G protein activation profiles of the D2S, compared with the D2L isoform.Experimental Approach: We employed a NanoBRET‐based approach to G protein dissociation to interrogate the time‐resolved coupling profile of 3×HA‐tagged D2L and D2S to Gαi/o/z proteins in vitro.Key Results: Using dopamine as a D2 receptor agonist, we observed a more pronounced activation of Gαo and Gαz than Gαi proteins by D2L compared with D2S. This differentiation was not observed for D2S, which activated Gαo and Gαz with lower efficacy than D2L. These signalling differences were preserved on second messenger level and were not due to differences in receptor expression. Expanding to a set of seven full and partial D2 receptor agonists showed these effects were not restricted to dopamine but rather a mutual, receptor‐associated property. Contrasting this trend, we found that D2S activated G proteins faster than D2L upon full receptor activation.Conclusion and Implications: The findings highlight that both D2L and D2S are mechanistically able to activate all non‐visual Gαi/o proteins. Thereby, they add to previous reports about isoform‐specificity to certain Gαi/o proteins observed in specific cell types.LINKED ARTICLES: This article is part of a themed issue Complexity of GPCR Modulation and Signaling (ERNST). To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v182.14/issuetoc

11 November 2021 in Research Square
Verified
Preprint
Open access
PDF file
IHIndra Heckenbach
Indra Heckenbach
GMGarik Mkrtchyan
Garik Mkrtchyan
MEMichael Ben Ezra
Michael Ben Ezra
DBDaniela Bakula
Daniela Bakula
JMJakob Madsen
Jakob Madsen
MSMorten Scheibye-Knudsen
Morten Scheibye-Knudsen
Cellular senescence is a critical component of aging and many age-related diseases, but understanding its role in human health is challenging in part due to the lack of exclusive or universal markers. Using neural networks, we achieve high accuracy in predicting senescence state and type from the nuclear morphology of DAPI-stained human fibroblasts, murine astrocytes, murine neurons, and fibroblasts derived from premature aging diseases in culture. After generalizing this approach, the predictor recognizes an increasing rate of senescent cells with age in H&E-stained murine liver tissue and human dermal biopsies, suggesting that alterations in nuclear morphology is a universal feature of senescence. Evaluating corresponding medical records reveals that individuals with a higher rate of senescent cells have a significantly decreased rate of malignant neoplasms, lending support for the protective role of senescence in limiting cancer development. Additionally, we find a positive association with lower significance for other conditions, including osteoporosis, osteoarthritis, hypertension, cerebral infarction, hyperlipidemia, and hypercholesteremia. In sum, we introduce a predictor of cellular senescence based on nuclear morphology that is applicable across tissues and species and is associated with health outcomes in humans.

19 June 2026 in ChemRxiv
Verified
Preprint
Open access
JMJakob S. Madsen
Jakob S. Madsen
SASara Angelucci
Sara Angelucci
CPChristopher L. Porterfield
Christopher L. Porterfield
XLXiaoting Liu
Xiaoting Liu
AHAlexander S. Hauser
Alexander S. Hauser
We introduce ModernMolBERT, an encoder-only transformer model for small-molecule representation learning. ModernMolBERT adapts the ModernBERT architecture to molecular language modelling and pairs it with a SELFIES-aware Atom Pair Encoding (APE) tokeniser. Both released variants (small and base) are pre-trained with masked language modelling on approximately 2.4M unique SELFIES strings from ChEMBL 36 and evaluated as frozen molecular embedders on 25 binary classification benchmarks. ModernMolBERT-base attains a mean ROC-AUC of 77.9 (reported on a 0 to 100 scale), competitive with a strong fingerprint baseline and improving on comparable pre-trained string encoders by roughly five points. ModernMolBERT provides a compact, reproducible, open-source foundation for SELFIES-based molecular representation learning; we release the model weights, the APE tokeniser, and training code.